A rivaroxaban hatásmechanizmusáról

Translated title of the contribution: On rivaroxaban's mechanism of effect

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A new era of anticoagulant therapy is approaching. No new oral anticoagulants have been introduced for seventy years. However, two large groups of anticoagulants (molecules with anti-FXa and anti-Flla acitivity) are currently at advanced stages of clinical trials. This publication summarises the most important information on the mechanism of effect of the anti-FXa drug rivaroxaban. The possible advantages of the "direct" effect and the anti-FXa effect are emphasized. The most significant drug interactions of the new anticoagulant are also presented.

Original languageHungarian
Pages (from-to)813-816
Number of pages4
JournalLege Artis Medicinae
Volume20
Issue number12
Publication statusPublished - Dec 2010

Fingerprint

Anticoagulants
Drug Interactions
Clinical Trials
Rivaroxaban
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A rivaroxaban hatásmechanizmusáról. / Boda, Z.

In: Lege Artis Medicinae, Vol. 20, No. 12, 12.2010, p. 813-816.

Research output: Contribution to journalArticle

Boda, Z. / A rivaroxaban hatásmechanizmusáról. In: Lege Artis Medicinae. 2010 ; Vol. 20, No. 12. pp. 813-816.
@article{ef9bec33c6264f96be5ca9a0b0dd5bf5,
title = "A rivaroxaban hat{\'a}smechanizmus{\'a}r{\'o}l",
abstract = "A new era of anticoagulant therapy is approaching. No new oral anticoagulants have been introduced for seventy years. However, two large groups of anticoagulants (molecules with anti-FXa and anti-Flla acitivity) are currently at advanced stages of clinical trials. This publication summarises the most important information on the mechanism of effect of the anti-FXa drug rivaroxaban. The possible advantages of the {"}direct{"} effect and the anti-FXa effect are emphasized. The most significant drug interactions of the new anticoagulant are also presented.",
keywords = "Anti-FXa, New direct oral anticoagulants, Rivaroxaban",
author = "Z. Boda",
year = "2010",
month = "12",
language = "Hungarian",
volume = "20",
pages = "813--816",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "12",

}

TY - JOUR

T1 - A rivaroxaban hatásmechanizmusáról

AU - Boda, Z.

PY - 2010/12

Y1 - 2010/12

N2 - A new era of anticoagulant therapy is approaching. No new oral anticoagulants have been introduced for seventy years. However, two large groups of anticoagulants (molecules with anti-FXa and anti-Flla acitivity) are currently at advanced stages of clinical trials. This publication summarises the most important information on the mechanism of effect of the anti-FXa drug rivaroxaban. The possible advantages of the "direct" effect and the anti-FXa effect are emphasized. The most significant drug interactions of the new anticoagulant are also presented.

AB - A new era of anticoagulant therapy is approaching. No new oral anticoagulants have been introduced for seventy years. However, two large groups of anticoagulants (molecules with anti-FXa and anti-Flla acitivity) are currently at advanced stages of clinical trials. This publication summarises the most important information on the mechanism of effect of the anti-FXa drug rivaroxaban. The possible advantages of the "direct" effect and the anti-FXa effect are emphasized. The most significant drug interactions of the new anticoagulant are also presented.

KW - Anti-FXa

KW - New direct oral anticoagulants

KW - Rivaroxaban

UR - http://www.scopus.com/inward/record.url?scp=78951472762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78951472762&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:78951472762

VL - 20

SP - 813

EP - 816

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 12

ER -